Drugs / Treatment Arm - high dose ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03456817 Background | Jul 2020 → May 2025 | graft versus host disease | AHS Cancer Control Alberta | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Treatment Arm - high dose ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03456817 ↗ |
| Known as | MTX | “MTX is given 15 mg/m2 IV on day +1 \& 10 mg/m2 on days +3, +6 \& +11 posttransplant.” NCT03456817 ↗ |
| Route | Intravenous | “MTX is given 15 mg/m2 IV” NCT03456817 ↗ |